F DTG	- 4000 MOD										
(REV 10-9	D-1390-MOD 96)	U. S. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 33511-US-PCT								
	TRANSMITTAL LETTER TO	THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
	DESIGNATED/ELECTED	OFFICE (DO/EO/US)	10/579,876								
	CONCERNING A FILING	UNDER 35 U.S.C. 371									
INTER	RNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
	EP2004/013179	19 November 2004 (19.11.04)	21 November 2003 (21.11.03)								
	OF INVENTION										
1H-IM	IDAZO(4,5-C)QUINOLINE DERIVA	TIVES IN THE TREATMENT OF PRO	TEIN KINASE DEPENDENT DISEASES								
APPL	ICANT(S) FOR DO/EO/US										
CAPR	ARO ET AL.		÷								
Applica	ant herewith submits to the United States	s Designated/Elected Office (DO/EO/US) th	ne following items and other information:								
1.	This is a FIRST submission of items of	concerning a filing under 35 U.S.C. 371.									
2.	This is a SECOND or SUBSEQUENT	submission of items concerning a filing und	der 35 U.S.C. 371.								
3. 🗌	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).										
4.	A proper Demand for International Predate.	eliminary Examination was made by the 19t	h month from the earliest claimed priority								
5. 🗌											
	 b. has been transmitted by the Ir 	nternational Bureau. (See Form PCT/IB/30)	8)								
6 🗆	c. is not required, as the applicat	tion was filed in the United States Receiving	Office (RO/US).								
6. 7.	Amendments to the claims of the Inter	cation into English (35 U.S.C. 371(c)(2)). rnational Application under PCT Article 19 (35 H S C 274/5/200								
_	a. 🔲 are transmitted herewith (requ	ired only if not transmitted by the Internation	nal Bureau).								
	 D. \(\subseteq \) have been transmitted by the 	International Bureau.	·								
	c. have not been made; howeverd. have not been made and will r	r, the time limit for making such amendmen	ts has NOT expired.								
8. 🔲	A translation of the amendments to the	e claims under PCT Article 19 (35 U.S.C. 3)	71 (c)(3)).								
9. ⊠ 10. □	An executed Declaration and Power of	f Attorney (original or copy) (35 U.S.C. 371.	(c)(A))								
10.	371(c)(5)).	ernational Preliminary Examination Report	under PCT Article 36 (35 U.S.C.								
	3. ((a)(a)).										
Items 1	1. to 16. below concern document(s)	or information included.									
11. 🔲	An Information Disclosure Statement L	under 37 CFR 1.97 and 1.98.									
12. 🗌	An assignment document for recording	g. A separate cover sheet in compliance wi	th 37 CFR 3.28 and 3.31 is included.								
13. 🔲	A FIRST preliminary amendment.										
	A SECOND or SUBSEQUENT prelimin	nary amendment.									
14. 🔲	An Application Data Sheet under 37 C	FR 1.76.									
15. 🔲	A substitute specification.										
16. 🔲	A change of power of attorney and/or a	address letter.									
17. 🔲	A computer-readable form of the seque	ence listing in accordance with PCT Rule 13	3ter.2 and 37 CFR 1.821-1.825.								
18. 🔲		ational Application under 35 U.S.C. 154(d)(4									
19. 🔲	A second copy of the English language	translation of the International application	under 35 U.S.C. 154(d)(4).								
20.	Other items or information:										

10/579,876				PCT/EP2004/013179 ATTORNEY'S 33511-US					DOCKET NUMBER S-PCT				
The following fees are submitted:										CALCULATIONS PTO USE			
									ONLY				
21. Basi	. Basic national fee							\$					
22. Examination Fee													
If International preliminary examination report was prepared by USPTO													
and all claims satisfy provisions of PCT Article 33(1)-(4)													
All other situations													
23. Search fee													
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international													
application to the USPTO as an International Searching Authority \$													
If International Search Report was prepared and provided to the Office \$ All other situations													
TOTAL OF 21, 22 AND 23 =									\$	0			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.													
Total Sheets	Extra	sheets		f each additional 5		n	R	ATE	7				
- 100 =		/50 =	thereof (ro	ound up to a whole	number)		V 0						
				No. 1			X \$	250	\$				
Surcharge of \$1	30 for fu	rnishing the	oath of dec	claration later than	⊠ 30				\$	130			
CLAIMS	eamest	NUMBI	onty date (3 ER FILED	37 CFR 1.492(e)). NUMBER E	XTRΔ		RA	re	 				
Total claims			- 20		-201105	X		50	\$	~			
Independent cla	ims	F OL A (84/0)	- 3			X		200	\$				
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360 TOTAL OF ABOVE CALCULATIONS =									\$	400			
Reduction of 1/2	for filing	by small e	ntity, if appl	icable Verified Sr	nall Entity	State	LCULA	HONS =	\$	130			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).								s					
SUBTOTAL =								\$	130	·			
Processing fee of \$130 for furnishing the English translation later than a 30 months from the earliest claimed priority date (37 CFR 1.492(f)).													
TOTAL NATIONAL FEE =								\$	130				
Fee for recording	the end	losed assig	nment (37	CFR 1.21(h)). The	assignme	ent m	ust be ac	companied	-	130			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$						
TOTAL FEES ENCLOSED =								\$	130				
									unt to	\$			
									be: refu	unded arged	\$		
a. A check	in the a	mount of \$_		to cover the	above fee	s is e	enclosed		CIT	arged	Ψ		
b. Please duplicat	charge D	eposit According this form in	ount No. 19	0-0134 in the name				nt of \$130 to	cover the	above	fees. A		
					lditional fo		.:-b						
Deposit	Account	No. 19-013	34 in the na	d to charge any ac me of Novartis.	ullional le	es wr	iich may i	oe required,	or credit a	any ove	rpayment to		
NOTE: Where a or (b)) must be f	n appro iled and	priate time I granted to	limit unde	er 37 CFR 1.494 or ne application to	r 1.495 has pending s	s not	been me	t, a petition	to revive	∍ (37 CI	FR 1.137(a)		
							•				1		
Send all correspondence to the address associated with Customer No. 001095, which is currently:													
Novartis							cNally)				
Corporate Intellectual Property Reg. No. 36 214													
One Health Plaza, Building 104 (862) 778-7898 East Hanover, NJ 07936-1080													
Last Hall	OVEI, INJ	01 900-108	U										